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The “Weight” of Obesity on 
Arterial Hypertension
Annalisa Noce and Nicola Di Daniele
Abstract
The prevalence of obesity and its related diseases are increasing worldwide. 
This phenomenon has been observed not only in adults but also in adolescents and 
children. Numerous scientific studies have revealed a direct correlation between 
the increase in blood pressure and weight gain. In fact, visceral fat can contribute 
to the rise in blood pressure because it is associated with an increased production of 
inflammatory cytokines (such as interleukin-1-β, tumor necrosis factor-α and inter-
leukin-6) and inflammatory factors (such as C-reactive protein), inducing endothe-
lial dysfunction and consequently arterial hypertension (AH). Insulin resistance, 
which develops in obese individuals, may represent an additional risk factor in the 
onset of AH. Postprandial hyperglycemia is not able to inhibit lipolysis, inducing 
a greater release of free fatty acids causing metabolic abnormalities, oxidative 
stress and vascular dysfunction. In this chapter, we will examine the mechanisms 
that correlate obesity to hypertension, such as the involvement of the sympathetic 
nervous system, metabolic and renal alterations. Finally, the pharmacological and 
nutritional treatment of obesity-related hypertension will be described.
Keywords: obesity, metabolic syndrome, renin-angiotensin system,  
obesity-hypertension link, anti-obesity drugs
1. Introduction
The World Health Organization (WHO) defines obesity as the clinical condition 
in which a subject presents a body mass index (BMI) ≥ 30 kg/m2. This condition 
can be further classified in three stages: stage 1 BMI 30-34.99 kg/m2, stage 2 BMI 
35–39.99 kg/m2 and stage 3 BMI ≥ 40 kg/m2 [1].
Obesity and being overweight (BMI ≥ 25 kg/m2) [2] have become in recent years 
a substantial health burden due to their growing prevalence.
In the USA, the prevalence of obesity in adults has increased by 39.6% from 2015 
to 2016, and it is forecasted to reach the astounding number of 2.1 billion people by 
2030 [3]. In China, the percentage of obese men and women in 2013 was, respectively, 
of 3.8 and 5.8%, while in Japan it was of 4.5 and 3.3%. In Eastern Europe during 2013, 
the percentage of obese adult subjects did not differ much from that in the USA: 
21% of the adult population resulted obese, with equal gender distribution [2]. In 
Germany, a recent study has highlighted that 35.4% of the adult population was over-
weight and the 21.3% was obese, in Italy 34.9% was overweight and 12.3% obese [4].
All epidemiologic studies conducted till date have confirmed that the global preva-
lence of obesity is constantly rising [5]. Therefore, it is becoming a sanitary emergency, 
both in terms of human resources and economically. In fact, it is worthy to consider 
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that excess of adipose tissue is associated with an increase in cardiovascular (CV) risk 
and with the precocious insurgence of CV diseases [6]. It has been underlined that 
obesity is characterized by an augmented activation both the sympathetic nervous 
system (SNS) [7], and of renin-angiotensin-aldosterone system (RAAS), which play 
a fundamental role in the physiopathology of AH [8]. It is estimated that about 75% 
of hypertension incidence is directly correlated to the contextual presence of obesity, 
characterizing the form of obesity-related hypertension [9, 10].
2. Physiopathological mechanisms of obesity-related hypertension
The association between body weight and arterial pressure was made for the first 
time during the 1960s, in the Framingham Heart Study [11]. However, the nature 
of such correlation remained unknown until the latter half of the 1980s, when a 
series of studies highlighted the possible mechanisms, which correlated these two 
clinical entities [12–14]. Such studies took inspiration from the clinical observation 
made by Vague [15], who observed that metabolic and CV complications linked 
to obesity were more frequent in subjects with a phenotype of “android” obesity 
(most fat localized in the upper part of the body) that with those with a “gynoid” 
phenotype (most fat localized in the inferior part of the body). Successively, during 
the 1980s, other population studies have been conducted which utilized the waist/
hip ratio as a quantitative index of the visceral fat, demonstrating that a higher 
ratio was correlated with a significant increase of CV risk [12–14]. Further studies 
shed light on the presence of insulin resistance in the android phenotype [16, 17]. 
Furthermore, the possible association between insulin resistance and the presence 
of AH was evaluated in both obese and non-obese subjects, constructing the basis 
for the comprehension of the physiopathological mechanisms of obesity-related 
hypertension [18, 19].
The accumulation of excess adipose tissue triggers a cascade of events, which 
induce a rise in blood pressure values in both children and adults [20, 21]. The phys-
iopathological mechanism at the basis of the insurgence of hypertension is complex, 
and encompasses the following: activation of the SNS through the action of hyper-
leptinemia and hyperinsulinemia, vascular damage caused by a chronic low-grade 
inflammatory state, endothelial dysfunction, oxidative stress and finally vasocon-
striction coupled with fluid retention modulated by the RAAS activation [22–24].
2.1 Increased SNS activity
In the condition of obesity-related hypertension, hyperactivation of the SNS 
can be observed [25]. In such mechanism, total body fat distribution plays a pivotal 
role, as microneurography studies have demonstrated that the grade of SNS activity 
is greater in subjects who present visceral fat distribution [26, 27]. Moreover, it has 
been shown that there is a direct correlation between SNS activation and the waist/
hip ratio [28].
Numerous studies have demonstrated that obesity induces the alteration of the 
arterial baroreceptor control of sympathetic activity, which involves inhibitory and 
excitatory components [25].
Commonly, with obesity, a reduction of the parasympathetic tone can be 
observed with an increase of sympathetic activity with a reduction of heart rate 
variability [29, 30]. On the contrary, with weight loss, the parasympathetic tone and 
the heart rate variability increase.
Obesity is also associated to tissue SNS activation, at the levels of the heart, 
kidney and musculoskeletal tissue [31, 32]. Specifically, obese subjects present an 
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increase of sympathetic renal nervous tissue activity, diagnosed by an increased 
concentration of renal norepinephrine [33]. Moreover, obese subjects with normal 
blood pressure have a suppressed cardiac SNS activity, while obese subjects with AH 
have an increase in cardiac SNS activity [33]. Consequently, it is hypothesized that 
the development of obesity-related hypertension plays a fundamental role in aug-
menting renal and cardiac sympathetic activity. In order to confirm such hypothesis, 
it is worth noting that renal denervation induces a reduction of blood pressure values 
and an increased sodium excretion in a canine model fed with a high fat diet [34].
Other mechanisms that would seem to be involved in the regulation of the 
activation of the SNS, determining other direct effects on CV homeostasis are 
hormonal, metabolic, inflammatory and endothelial factors. The possible rela-
tion between insulin and arterial blood pressure was initially quite controversial, 
however, recent studies have highlighted a possible role for such hormone in the 
physiopathological mechanism of obesity-related hypertension [35]. Since insu-
lin stimulates the SNS, and obese subjects have an increase in SNS activity, it is 
hypothesized that the stimulation of the SNS is also mediated by insulin [36]. Such 
hypothesis would also explain the physiopathological mechanism at the basis of 
the elevated blood pressure values that are recorded in central obesity. This would 
also seem to be supported by some studies that have shown a concomitant reduc-
tion of arterial blood pressure and SNS activity in obese subjects who underwent 
insulin level reduction thanks to a low calorie diet [37]. Moreover, chronic hyper-
insulinemia needs to be also correlated to an arterial dysfunction, which favors a 
mechanism of vasoconstriction. Insulin can exert a direct action on the kidney, 
by stimulating sodium reabsorption and consequently inducing sodium retention 
via direct interaction with renal tubules [38]. Therefore, obesity-induced hyperin-
sulinemia seems to contribute to the increase in arterial blood pressure values by 
acting on sodium retention, and the expansion of extracellular volume.
Another factor involved in SNS stimulation is leptin. This adipokine is produced 
by adipocytes, and its plasmatic concentration is directly correlated to the amount 
of fat mass of the subject [39]. Leptin induces appetite suppression and stimulates 
the SNS [40]. With regards to leptin concentration, gender variation has been 
observed: female individuals present higher hormonal levels and a greater receptor 
expression (ObR) compared to male subjects [41]. A possible explanation for such 
phenomenon has highlighted that subcutaneous adipose tissue, predominating 
in the female gender, produces a greater quantity of leptin compared to visceral 
adipose tissue [42].
Studies conducted on animal models have demonstrated that leptin infusion 
induces an increase in blood pressure values and SNS hyperactivation [43, 44].
From recent studies, it has emerged that leptin-mediated SNS stimulation could 
be seen as a mechanism to stabilize bodily weight and restore energetic equilib-
rium in obese patients, increasing energetic expenditure by stimulating brown fat 
thermogenesis [45].
2.2 Increased RAAS activity
Numerous studies have highlighted that urinary and plasmatic concentration 
of aldosterone is increased in obese subjects compared to normal weight subjects 
[46]. In particular, its plasmatic concentration results directly correlated with the 
quantity of visceral adipose tissue [47]. Various authors have shown how adipose 
tissue releases adipokines, which stimulate the adrenal glands to produce aldoste-
rone, independently from the plasmatic activity of renin [48–50]. Therefore, RAAS 
activation is directly involved in the development of obesity-related hypertension. 
Obese subjects, especially if they present a substantial visceral fat quota, often have 
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increased plasmatic renin activity, together with an enhancement in angiotensin 
converting enzyme (ACE), a greater concentration of aldosterone, angiotensinogen 
and angiotensin II [51]. In obese patients, RAAS activation is determined by a num-
ber of factors, some of which are constituted by physical renal compression induced 
by an increment in visceral fat, SNS hyperactivation and local activation of RAAS in 
the adipose tissue [52]. Adipose tissue, other than containing all RAAS components, 
is able to produce angiotensin II [53]. Even if in obese subjects the principal bulk of 
angiotensinogen continues to be produced by the liver (as in healthy subjects), it has 
been demonstrated that in obese patients, there is an increase of angiotensinogen 
produced by the adipose tissue [54]. To support this finding, an interesting study 
conducted on adipocyte-angiotensinogen deficient mice (AgtaP2) has demonstrated 
that a fat-rich diet induces blood pressure increase in wild type rats, but causes no 
pressure increase in AgtaP2 rats, even if both groups present an equal increase in 
weight and fat mass [55]. Moreover, it is worth to point out that RAAS of adipose 
tissue not only produces angiotensin II, through ACE enzymatic activity, but also 
uses a less common mechanism that relies on the enzymatic activity of cathepsins 
and chymases [56].
To prove the hypothesis that RAAS activity has a significant role in the patho-
genesis of obesity-related hypertension; a study has been conducted on obese 
subjects who have undergone bariatric surgery, which demonstrated a significant 
reduction in RAAS activity due to considerable weight loss [57].
A fundamental role in obesity-related hypertension is also carried out by aldo-
sterone, as obese subjects present elevated levels of this hormone [58, 59], and since 
weight loss is not only associated with reduced plasmatic renin activity but also with 
aldosterone, independently from sodium intake. As a final analysis, weight loss also 
induces a beneficial effect on blood pressure values [58].
Aldosterone increase has also been observed in obese adolescents [59] and obese 
menopausal women [60]. Moreover, one should consider that the highest levels of 
plasmatic renin activity, aldosterone and ACE have been highlighted in subjects 
with visceral obesity but not in subjects with peripheral obesity [61]. Goodfriend 
et al. have confirmed that in subject affected by visceral obesity, adipose tissue is 
involved in the excess production of aldosterone, through the action of aldosterone 
releasing factors [62].
2.3  Changes in kidney function and hemodynamic in obesity-related 
hypertension
Obese subjects present an elevated risk to develop chronic kidney disease [63]. 
During obesity, an expansion of extracellular volume and an increase in blood flow 
in many tissues that leads to increased cardiac output, can be observed [64]. The 
latter, increases in a consistent manner with weight gain, and part of such increase 
is closely correlated to the blood flow needed to supply the excess of adipose tissue. 
Such blood flow increase is appreciable not only at the adipose tissue level, but also 
in other organs and tissues such as the heart, the kidney, the gastro-intestinal appa-
ratus and the muscle [21, 65]. Excess blood flow, which can be observed at the level 
of other organs, is caused by the hypertrophy that such organs undergo because of 
obesity; it is secondary to increased metabolic demand and to the greater work load 
present in this pathological condition [66]. Renally, this translates into glomerular 
hyperfiltration that can be encountered in the initial phases of the pathology, 
which will successively progress in chronic kidney disease with reduced glomerular 
filtration [67]. During the initial stages of obesity, there is an augmented sodium 
tubular reabsorption with a consequent increase in sodium retention. In order to 
compensate such mechanism, the kidney undergoes vasodilation with subsequent 
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hyperfiltration and increased filtration of water and electrolytes. However, this 
compensatory mechanism is incomplete and induces an extracellular volume 
expansion with an increase in blood pressure values. Therefore, obesity induces an 
increase sodium tubular reabsorption in the kidney via different mechanisms such 
as neural, hormonal and reno-vascular. The first involving the SNS, the second 
insulin and aldosterone, and the third angiotensin II [68]. During obesity, even with 
the expansion of extracellular volume, renin secretion by the kidneys still occurs. 
This is due to the action exerted by fat accumulated in the renal medulla and in the 
peri-renal adipose tissue [10, 69].
2.4 Inflammation and obesity-related hypertension
In obese subjects, adipose tissue dysfunction can be observed. It is characterized 
by a reduction in protective factor concentration such as adiponectin, nitric oxide 
and prostaglandins, and an increased release of pro-inflammatory adipokines such 
as resistin, leptin and visfatin, with subsequent development of low-grade inflam-
mation. Cumulatively, this induces a metabolic and vascular dysfunction in the 
obese subjects [70, 71].
In pathologic conditions, adipocytes produce both inflammatory cytokines and 
extracellular matrix proteins, favoring the infiltration of immune cells in the adipose 
tissue and consequent inflammation [72]. In turn, the same infiltrative immune cells 
activate and release cytokines that can directly influence the adipocyte function or 
induce the secretion of pro-inflammatory adipokines. These effects are also evident 
at the level of the perivascular adipose tissue, particularly when adjacent to athero-
sclerotic or dysfunctional vessels in hypertensive subjects. In fact, in AH, perivas-
cular adipose tissue inflammation can be observed. This kind of inflammation, is 
in turn involved in the dysfunction of vessels [73], favoring vasoconstriction and 
inhibiting endothelium-dependent vasodilation [72]. Such functional changes will 
have correspondent morphological changes: perivascular adipose tissue becomes 
pro-inflammatory, dedifferentiated and metabolically active. This tissue will pro-
duce a greater number of chemokines, such as RANTES, involved in the activation 
of monocyte/macrophages and CD8+ T cells. Moreover, an increase in sympathetic 
innervation can be observed at the level of the perivascular adipose tissue, which is 
also involved in the mechanism of obesity-related hypertension [74].
Hypertensive subjects present at the perivascular adipose level an increment 
in T lymphocytes, antigen-presenting cells and factors involved in endothelial 
dysfunction. These factors explain the persistent relationship between hyperten-
sion and the atherosclerotic process [75]. During AH, one can observe in the 
perivascular adipose tissue an increase in both CD4 and CD8 and the expression of 
pro-inflammatory cytokines (TNF-α and INF-γ) [73, 76]. The pro-inflammatory 
cytokines modulate smooth muscle cell contraction, their migration and prolifera-
tion [77]. However, it is also worth considering that leptin is structurally similar 
to IL-6, IL-12 and IL-15 and is capable to induce leukocyte activation, chemotaxis, 
free radical production and the expression of endothelial adhesion molecules at the 
level of vascular smooth vessel cells. Moreover, pro-inflammatory cytokines (IL-17A 
and TNF-α) induce in the adipose tissue an increased production of leptin and resis-
tin, which in turn cause an augmented expression of VCAM-1 and ICAM-1, causing 
vascular dysfunction and oxidative stress [78].
2.5 Obstructive sleep apnea
Obstructive sleep apnea (OSA) represents together with obesity, an independent 
risk factor for the development of AH.
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The first study, which highlighted the presence of fluctuations in arterial blood 
pressure in course of complete or partial OSA, was conducted in 1972 [79]. OSA is 
characterized by a series of events that induce the collapse of the superior airways 
during sleep with consequent intermittent hypoxia, hypercapnia, negative intratho-
racic pressure and increased activation of the SNS [80, 81]. Therefore, the intermit-
tent hypoxia observed during OSA (which also activates the SNS) contributes to the 
development of obesity-related hypertension [82]. OSA-induced SNS activation is 
caused by a dual mechanism: on one hand from the stimulation of peripheral che-
moreceptors, and on the other by the formation of ROS that contribute to systemic 
inflammation and endothelial dysfunction [83].
During hypoxia, it has been demonstrated that endothelin, which has a vaso-
constrictor action is released [84], with the improvement of oxygenation instead, 
there is a decreased production of endothelin and consequent vasodilation. Phillips 
et al. have suggested that the cyclical alterations of endothelin production in OSA 
patients can contribute to the insurgence of AH [85]. Such clinical observations 
have been confirmed on OSA murine models [86]. Moreover, OSA patients present 
a higher incidence of non-dipping of nocturnal systolic pressure, indicator of an 
increased adrenergic tone [87].
3. Therapeutic approaches to the obesity-related hypertension
According to the 8th report of the Joint National Committee (JNC8), normal 
blood pressure systolic values are inferior to 130 mmHg and normal diastolic values 
are inferior to 80 mmHg [88].
In order to have reliable measurements, ESC/ESH recommends to perform 
three of them in an ambulatories setting, with intervals of 1 or 2 min between each 
reading. Moreover, it is advised to perform additional measurements, if the first one 
differ more than 10 mmHg between one another. The blood pressure value that will 
be given by an average of the last two readings [89].
Even if the definition and the categorization of AH have varied over time, there 
is a consensus that is persistent. The therapeutic target is fixed around values equal 
or inferior to 130/80 mmHg [89, 90].
The therapeutic approach of obesity-related hypertension is based on a pharma-
cological therapy (anti-hypertensive and anti-obesity pharmaceuticals) associated 
to a nutritional/compartmental intervention (Figure 1). A healthy lifestyle is a valid 
support to pharmacological therapy and allows the correction of certain deleteri-
ous habits such as physical activity, hypercaloric diet, sodium-rich diet and alcohol 
abuse.
3.1 Anti-hypertensive drugs
3.1.1 RAAS inhibitors
Numerous studies have suggested diuretics is RAAS antagonists are particularly 
effective in obese subjects [91, 92]. In fact, as previously described, since angio-
tensin is overexpressed in obesity and given its role in the development of obesity-
related hypertension, ACE-inhibitors and angiotensin II receptor blockers (ARBs) 
are considered a valid therapeutic approach in such patients.
Moreover, when comparing ACE-inhibitors and ARBs to β-blockers and thiazide 
diuretics, it is apparent that RAAS antagonists are seldom associated to new cases of 
diabetes and induce less insulin resistance [93, 94]. Furthermore, ACE-inhibitors and 
ARBs do not appear correlated with weight gain, and carry out a nephroprotective 
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action in diabetic patients, which is a frequent comorbidity in obese subjects. These 
pharmaceuticals also induce a 30% reduction of left ventricular hypertrophy, which 
has a high prevalence in subjects affected by obesity-related hypertension [95, 96].
In support of the above statements, a study conducted on 6083 hypertensive 
subjects (65–84 years of age) with an average BMI of 27.4 kg/m2, has highlighted 
that starting the anti-hypertensive treatment with ACE-inhibitors will lead to a 
better outcome compared to an intervention with diuretics, independently of the 
improvement in blood pressure values [97].
3.1.2 Diuretics and β-blockers
Even if treatment with thiazide diuretics is frequently recommended in patients 
with AH [98], it must be kept in consideration that they present some dose-corre-
lated collateral effects such as insulin resistance, hyperuricemia and dyslipidemia. 
Moreover, in obese patients who have a predisposition for type 2 diabetes mellitus 
and metabolic syndrome, this kind of pharmaceutical approach is harmful and 
should be avoided [8].
To demonstrate this, an interesting open label, randomized study conducted on 
CV disease free and non-diabetic, hypertensive patients had shown that the adverse 
metabolic effects related to the treatment with thiazide diuretics and β-blockers 
were more frequent in subjects with abdominal obesity. Such adverse metabolic 
effects manifested after only 9 weeks from the start of the treatment [99].
Therefore, according to guidelines such pharmaceuticals, should be used with 
caution in patients who are at risk of developing metabolic syndrome or altered 
fasting glucose, in order to avoid the insurgence of diabetes and other long-term 
complications [100, 101].
It is recommended to use a low dose of thiazides in case of need, in association 
with a careful monitoring of the lipid and glycemic profile. β-Blockers, in addition 
to inducing insulin resistance, are associated to body weight gain, because they 
are thought to reduce thermogenesis induced by diet and velocity of fat oxidation 
[102, 103]. In obese patients, the use of β-blockers should be limited to subjects with 
a precise CV indication (namely, cardiac insufficiency and previous myocardial 
infarction).
Figure 1. 
Therapeutic approach of obesity-related hypertension.
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3.1.3 Other antihypertensive drugs
Calcium antagonists are antihypertensive drugs that induce diuresis and natri-
uresis, without exerting any effect on glucose and lipid metabolism.
They are constituted by two subclasses, such as non-dihydropyridines and dihy-
dropyridines, with notably different pharmacological effects. The first are normally 
used for the treatment of cardiac arrhythmia and seem to have an anti-proteinuric 
effect, similar to that induced by ACE inhibitors [104–107], and seem to slow down 
the progression of diabetic nephropathy [108].
On the other hand, dihydropyridines seem to heighten albuminuria, a factor cor-
related to an increased CV risk [109]. Such increase seems to be caused by a dilation 
of the preglomerular afferent arteriole with a consequent increase of intraglomeru-
lar pressure [110].
An analysis by Avoiding Cardiovascular Events through Combination Therapy 
in Patients Living with Systolic Hypertension (ACCOMPLISH) has evaluated which 
type of anti-hypertensive treatment could have an impact on the CV outcome of 
patient based on their body surface area (evaluated thanks to their BMI). It has 
been highlighted that, while thiazide treatment induces minor CV protection in 
normal subjects compared to obese ones, patients treated with calcium antagonist 
(amlodipine) did not present differences in CV protection according to their 
BMI. Therefore, calcium antagonists appear better at exerting CV protecting action 
on hypertensive non-obese subjects [111].
Another clinical study has showed important differences on the CV mortality of 
patients treated with calcium antagonists, β-blockers or sartans, highlighting that 
patients treated with amlodipine were majorly protected from CV events and had 
a reduced risk of developing diabetes compared to those treated with β-blockers 
(atenolol) [112]. This study did not examine the impact induced by the body surface 
area on CV protection. Therefore, calcium antagonists emerge as a pharmaceutical 
alternative in the treatment of obesity-related hypertension with potential benefits 
[113], even if more clinical randomized trials are required to fully understand their 
beneficial effects [114, 115].
A retrospective observational study conducted in southern Italy, has examined 
what type of pharmaceuticals are used for the treatment of obesity-related hyperten-
sion in a clinical practice. It has highlighted that the clinicians do not differentiate 
between pharmaceuticals to use in relationship to the grade of obesity or the presence 
of metabolic syndrome. Moreover, it has been observed that antihypertensive phar-
maceuticals, which cause negative effects on weight and metabolic profile, are still 
largely used in subjects at risk [116]. Such study underlines the necessity to conduct 
clinical randomized trials on a large population of patients affected by obesity-related 
hypertension, in order to standardize pharmacological antihypertensive therapy based 
on obesity severity, CV protection and limitation of metabolic complications.
3.2 Anti-obesity drugs
Lifestyle changes perform a key role in the treatment of obesity-related hyper-
tension. According to the Obesity Education Initiative Working Group guidelines, 
anti-obesity drugs should represent a support strategy in the treatment of subjects 
with BMI ≥30 kg/m2 without associated comorbidities, and in subjects with 
BMI ≥ 27 kg/m2 with comorbidities [117]. Drugs used in the treatment for obesity 
can be divided into the following categories: (1) inhibitors of nutrient absorption 
(orlistat and acarbose); (2) appetite suppressors (phentermine and lorcaserin); (3) 
drugs used in the treatment for diabetes that determine weight loss (metformin and 
incretin therapy: GLP1 agonists and DPP-4 inhibitors) [8, 113].
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3.2.1 Inhibitors of nutrient absorption
Orlistat is a gastrointestinal lipase inhibitor that causes a consequent reduction 
in absorption of dietary fat. Its use in clinical practice is limited by gastrointestinal 
adverse effects, which occur especially if patients have a high fat diet [118]. A study 
aimed at evaluating orlistat and sibutramine (serotonin and norepinephrine re-
uptake inhibitor acting as an appetite suppressor, removed from the market in 2010 
because of associated increased CV risk) [119] has highlighted the same level of 
efficacy in reducing BMI, body weight and waist circumference. Moreover, orlistat-
treated subjects presented a significant reduction in blood pressure values, while 
they remained stable in sibutramine-treated subjects [120].
In order to reduce gastrointestinal adverse effects related to orlistat ingestion, a 
half dose pill (60 mg) has been produced that is still able to reduce fat absorption of 
25% [121, 122].
A study has evaluated as secondary outcome, long-term effects related to orlistat 
treatment, demonstrating that about two-third of the weight loss was maintained 
over a 2 years compared to the placebo-treated group. The pharmaceutical interven-
tion was combined during the first year with a hypocaloric diet, and during the 
second year with a weight maintaining diet. Moreover, patients treated with orlistat 
full dose (120 mg), presented after 2 years an improvement in systolic pressure 
values [123].
Acarbose is an oral antidiabetic. It inhibits intestinal alpha-glucosidase and 
pancreatic alpha-amylase. By inhibiting these enzymes, such drug impedes the 
digestion and absorption of complex sugars. It has been highlighted that acarbose 
induces a modest reduction in body weight [124]. A study performed on 110 obese 
subjects with BMI between 32 and 38 kg/m2, who underwent a hypocaloric diet for 
10–16 weeks and substantial weight loss, has highlighted that acarbose treatment 
does not induce significant effects on the stabilization of weight loss [125], confirm-
ing the modest effect of the drugs in body weight reduction.
3.2.2 Appetite suppressors
Appetite control represents a cardinal step in the treatment of obesity. Studies 
finalized to evaluate appetite control have demonstrated the existence of an 
endogenous system, which is able to stimulate, through orexigenic substances, 
and inhibit, through anorexigenic substances, food intake [126, 127]. Leptin and 
serotonin are two endogenous ligands which act contemporaneously inhibiting 
the hypothalamic feeding center, and stimulating the satiety center [128]. An 
important appetite suppressor to cite is fenfluramine, which was successively 
removed from the market because of its severe collateral effects. It acted on 
serotonin release at the level of the hypothalamus and induced significant weight 
loss [129].
In 2012, the Food Drug Administration (FDA) has approved the use of lorcaserin 
for the treatment of obesity [130]. This drug is a serotonin 2C receptor agonist (5-HT2c), 
and appears to be efficacious in co-adjuvating weight loss in obese and overweight 
subjects in association with a hypocaloric diet and increased physical activity [131].
Lorcaserin, being selective for 5-HT2c receptors, represents a more efficacious 
and safe drug, compared to other non-selective serotoninergic appetite suppressor 
drugs because it does not induce CV collateral effects [132].
Another drug belonging to the class of the appetite suppressors is phentermine, 
an adrenergic agonist that, thanks to the central nervous system and SNS activa-
tion, is capable to determine reduced food intake and increase basal metabolism 
[133]. The FDA approves phentermine use to treat obesity for a period no greater 
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than 3 months. Since it causes an increase in the release of norepinephrine, it could 
lead to an increase in blood pressure values and cardiac frequency [134].
3.2.3 Drugs used in the treatment for diabetes that determine weight loss
Drugs used for the treatment of diabetes commonly determine weight loss and 
reduced fat accumulation. For overweight and obese subjects suffering of diabetes, 
the FDA has approved the use of hypoglycemic drugs, which are associated to 
weight loss and blood pressure reduction. Even if the effect is modest, it is however 
to be considered beneficial given the weight gain that is frequently associated with 
insulin and insulin secretagogue analogs.
Metformin is an oral hypoglycemic drug, used in type II diabetes treatment, that 
is capable of inducing modest weight loss as a consequence of a reduced hepatic 
production and intestinal absorption of glucose, and through the improvement of 
insulin sensitivity [135]. Such drug, as demonstrated by the Diabetes Prevention 
Program trial [136], is efficacious in reducing body weight in a follow-up period 
of 2.8 years in overweight diabetic subjects. However, metformin does not appear 
useful in reducing blood pressure, as was demonstrated in a series of clinical trials 
in which lifestyle modification resulted notably more efficacious in the control of 
blood pressure compared to this type drug [137].
Incretins are intestinal hormones secreted by enteroendocrine cells in the circu-
latory stream, few minutes after feeding. They regulate the quantity of post-feeding 
insulin secretion. There are two endogenous incretins such as glucose-dependent 
insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1); both are rapidly 
metabolized an enzyme called dipeptidyl peptidase-4 (DPP-4). These hormones, 
increasing insulin release by β pancreatic cells and inhibiting glucagon release, play 
an important role in glucose homeostasis. GLP-1 is the most abundant, but cannot 
be used for therapeutic scopes given its rapid degradation by DPP-4.
In 2005, exenatide was released, an injectable GLP-1 agonist, which mimics 
endogenous GLP-1 but has a prolonged action. Exenatide increases glucose-depen-
dent insulin secretion, suppresses glucagon secretion and slows down gastric filling. 
Therefore, it is hypothesized that exenatide could have a role in the treatment for 
obesity, since it induced a sense of satiety and reduced food intake.
DPP-4 inhibitors (sitagliptin, saxagliptin and linagliptin) are pharmaceuticals 
which increase endogenous plasmatic levels of active incretins, prolonging their 
action [138]. Moreover, they also reduce the degradation of many vasoactive 
peptides. Studies on animal models of ischemia/reperfusion have demonstrated a 
positive effect of DPP-4 inhibitors. Endogenous GLP-1 exerts protective effects on 
the myocardium and has a vasodilatory action [139]. A study that compared differ-
ent pharmaceutical therapies to tackle type II diabetes mellitus, such as exenatide 
and sitagliptin, has demonstrated that incretin treatment was associated with 
superior weight loss compared to the insulin-treated group. Weight loss was associ-
ated to a statistically significant systolic and diastolic blood pressure reduction in all 
the treated groups [140].
4. Life style management
The most common consequences related to obesity are the insurgence of essen-
tial AH, diabetes mellitus, chronic kidney disease, metabolic diseases, etc. [5, 141, 
142]. Even if antihypertensive drugs are of primary importance in the treatment of 
AH, they should always be associated with healthy eating habits, adequate levels of 
physical activity and a correct lifestyle [143].
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For this reason, it would be advised that hypertensive-obese patients follow 
nutritional counseling in order to evaluate their food habits and levels of physical 
activity [144]. In fact, incorrect food habits, scarce levels of physical activity and 
psychological factors such as depression can contribute to weight gain [145].
Nutritional intervention finalized to achieving weight loss in hypertensive-obese 
patients, should be personalized. Different types of diet exist, for example, strongly 
hypocaloric diet, balanced slightly hypocaloric diet, low-sodium diet, hypolipidic 
diet, hypoglucidic diet and hyperproteic diet. In whichever case, the common result 
should be weight loss and reduction of abdominal fat [146].
In recent years, a type of nutritional intervention that has had notable success 
(thanks to numerous clinical trials) is the “dietary approaches to stop hypertension” 
(DASH) diet. The DASH diet was formulated for the first time by the National 
Institute of Health (NIH) in the 1990s, and was object of many research studies 
[147]. It promoted the ingestion of vegetable proteins, fibers, fresh vegetables, 
fruits, extra-virgin olive oil and dried fruits, while suggesting a reduction in animal 
fats, simple sugars and processed meat. Trials have demonstrated how reduced salt 
consumption potentiated beneficial effects linked to DASH diet, inducing a reduc-
tion in systemic arterial pressure in all patients.
Progressive reduction in energy expenditure associated to increased caloric 
intake translates into weight gain, which finally amounts to obesity [120].
For this reason lifestyle, and specifically physical activity, has a role of primary 
importance in the maintenance of a healthy status both in primary and secondary 
prevention [148]. Numerous studies suggest that physical activity has a beneficial 
effect in subjects affected by AH, to the point of being compared to pharmaceuti-
cal intervention [149, 150]. Thanks to recent technologies, it has been possible to 
develop network meta-analysis (NMA) models able to compare the efficacy of 
physical activity and pharmacotherapy alone.
A meta-analysis by Naci and Ioannidis [150] has highlighted how physical activ-
ity alone elicits similar results to pharmacological therapy in terms of reduction of 
mortality in hypertensive patients. Such reduction has been studied in patients with 
coronary heart disease, post-infarct rehabilitation, cardiac insufficiency and in the 
prevention of diabetes. A recent study by Dempsey et al. [151] has compared seven 
continuative hours of inactivity to 3 min of light physical activity every 30 min (6 min 
of physical activity per hour). Such light physical activity, significantly reduced 
systolic and diastolic arterial blood pressure values, and reduced hematic norepi-
nephrine values.
Thus, it is evident that physical activity plays a pivotal role in the insurgence and 
management of AH. The challenge for the future will be to identify, using NMAs, 
different types of physical activity and pharmaceuticals that can be administered in 
a personalized manner based on the subject’s unique characteristics.
Substantial medical literature has tried to identify the mechanisms relating body 
weight control and cigarette smoke [152].
Even if, an increase in body weight was highlighted following smoking cessation 
(due to an increase in caloric intake because of the lack of smoking), many studies 
have also stated that this is a transitory condition [153]. In fact, it has been demon-
strated that the weight gain straight after smoking cessation, normalizes in about 6 
months with the re-establishment of the normal energetic intake [154].
Alcohol consumption has been a part of food culture since antiquity. Even if 
there are potential beneficial effects that reside in compounds present in alcoholic 
beverages, like in red wine, red wine, they have a caloric intake of 7.1 kcal/g of 
alcohol, therefore not recommended in obese subjects [155]. For this reason, alcohol 
intake should be controlled and modest, and in order to attain its beneficial poten-
tial the quality should also be considered [156].
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5. Conclusions
Obesity-related hypertension represents a public health problem, especially 
as hypertensive-obese subjects has notably enhanced and precocious CV-related 
morbidity and mortality compared to the general population. It is therefore use-
ful to act as promptly as possible, by intervening with strategies to contrast the 
insurgence excessive weight gain, obesity and their relative comorbidities such 
as obesity-related hypertension. It would be optimal to carry out an educational 
scheme aim at adolescents, in order to educate the population to undertake a 
correct lifestyle, which will contrast the insurgence of problems cited above later 
in life. A correct lifestyle is characterized by the combination of constant levels of 
physical activity and a balanced diet, taking as models the DASH Diet and/or the 
Mediterranean one. Once a subject develops obesity and hypertension, a pharma-
ceutical approach (to control systemic arterial blood pressure and obesity) should 
be flanked to the dietary intervention.
Acknowledgements
We are grateful to Dr Georgia Wilson Jones for the language revision of the 
manuscript. We are indebted to Dr. Giulia Marrone and Dr Manuela Di Lauro for 
their technical assistance.
Conflict of interest
The authors declare no conflict of interest.
Author details
Annalisa Noce* and Nicola Di Daniele
Division of Medical Sciences, Internal Medicine-Center of Hypertension and 
Nephrology Unit, Department of Systems Medicine, Tor Vergata University, Rome, 
Italy
*Address all correspondence to: annalisa.noce@uniroma2.it
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
13
The “Weight” of Obesity on Arterial Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.87774
[1] World Health Organization. 
Obesity: Preventing and managing 
the global epidemic. Report of WHO 
Consultation. WHO Technical Report 
Series 894. 2000
[2] Ng M, Fleming T, Robinson M, 
Thomson B, Graetz N, Margono C, 
et al. Global, regional, and national 
prevalence of overweight and obesity in 
children and adults during 1980-2013: 
A systematic analysis for the Global 
Burden of Disease Study 2013. Lancet. 
2014;384:766-781. DOI: 10.1016/
S0140-6736(14)60460-8
[3] Benjamin EJ, Blaha MJ, Chiuve SE, 
Cushman M, Das SR, Deo R, et al. 
Heart disease and stroke Statistics-2017 
update: A report from the American 
Heart Association. Circulation. 
2017;135:e146-e603. DOI: 10.1161/
CIR.0000000000000485
[4] DiBonaventura M, Nicolucci A, 
Meincke H, Le Lay A, Fournier J.  
Obesity in Germany and Italy: 
Prevalence, comorbidities, and 
associations with patient outcomes. 
ClinicoEconomics & Outcomes 
Research. 2018;10:457-475. DOI: 
10.2147/CEOR.S157673
[5] Chooi YC, Ding C, Magkos F. The 
epidemiology of obesity. Metabolism. 
2019;92:6-10. DOI: 10.1016/j.
metabol.2018.09.005
[6] Fox CS, Pencina MJ, Wilson PW, 
Paynter NP, Vasan RS, D'Agostino RB Sr. 
Lifetime risk of cardiovascular disease 
among individuals with and without 
diabetes stratified by obesity status in 
the Framingham heart study. Diabetes 
Care. 2008;31:1582-1584. DOI: 10.2337/
dc08-0025
[7] Canale MP, Manca di Villahermosa S, 
Martino G, Rovella V, Noce A,  
De Lorenzo A, et al. Obesity-
related metabolic syndrome: 
Mechanisms of sympathetic 
overactivity. International Journal of 
Endocrinology. 2013;2013:865965. DOI: 
10.1155/2013/865965
[8] Landsberg L, Aronne LJ, Beilin LJ,  
Burke V, Igel LI, Lloyd-Jones D, 
et al. Obesity-related hypertension: 
Pathogenesis, cardiovascular risk, and 
treatment: A position paper of The 
Obesity Society and the American 
Society of Hypertension. Journal of 
Clinical Hypertension (Greenwich, 
Conn.). 2013;15:14-33. DOI: 10.1111/
jch.12049
[9] Go AS, Mozaffarian D, Roger VL, 
Benjamin EJ, Berry JD, Blaha MJ, et al. 
Executive summary: Heart disease and 
stroke statistics. 2014 update: A report 
from the American Heart Association. 
Circulation. 2014;129(3):399-410
[10] Leggio M, Lombardi M, Caldarone E,  
Severi P, D’Emidio S, Armeni M,  
et al. The relationship between 
obesity and hypertension: An updated 
comprehensive overview on vicious 
twins. Hypertension Research. 
2017;40:947-963. DOI: 10.1038/
hr.2017.75
[11] Kannel WB, Brand N, Skinner JJ Jr,  
Dawber TR, McNamara PM. The 
relation of adiposity to blood pressure 
and development of hypertension. The 
Framingham study. Annals of Internal 
Medicine. 1967;67:48-59
[12] Lapidus L, Bengtsson C, Larsson B, 
Pennert K, Rybo E, Sjostrom L.  
Distribution of adipose tissue and risk 
of cardiovascular disease and death: 
A 12 year follow up of participants 
in the population study of women in 
Gothenburg, Sweden. British Medical 
Journal (Clinical Research Ed.). 
1984;289:1257-1261
[13] Larsson B, Svardsudd K, Welin L,  
Wilhelmsen L, Bjorntorp P, Tibblin G.  
References
Crosstalk in Biological Processes
14
Abdominal adipose tissue distribution, 
obesity, and risk of cardiovascular 
disease and death: 13 year follow up of 
participants in the study of men born in 
1913. British Medical Journal (Clinical 
Research Ed.). 1984;288:1401-1404
[14] Cassano PA, Segal MR, Vokonas PS,  
Weiss ST. Body fat distribution, 
blood pressure, and hypertension. A 
prospective cohort study of men in 
the normative aging study. Annals of 
Epidemiology. 1990;1:33-48
[15] Vague J. The degree of masculine 
differentiation of obesities: A factor 
determining predisposition to diabetes, 
atherosclerosis, gout, and uric calculous 
disease. American Journal of Clinical 
Nutrition. 1956;4:20-34. DOI: 10.1093/
ajcn/4.1.20
[16] Kissebah AH, Vydelingum N,  
Murray R, Evans DJ, Hartz AJ, Kalkhoff 
RK, et al. Relation of body fat distribution 
to metabolic complications of obesity. 
The Journal of Clinical Endocrinology 
and Metabolism. 1982;54:254-260. DOI: 
10.1210/jcem-54-2-254
[17] Krotkiewski M, Bjorntorp P, 
Sjostrom L, Smith U. Impact of obesity 
on metabolism in men and women. 
Importance of regional adipose tissue 
distribution. The Journal of Clinical 
Investigation. 1983;72:1150-1162. DOI: 
10.1172/JCI111040
[18] Ferrannini E, Buzzigoli G, 
Bonadonna R, Giorico MA, Oleggini M,  
Graziadei L, et al. Insulin resistance 
in essential hypertension. The 
New England Journal of Medicine. 
1987;317:350-357. DOI: 10.1056/
NEJM198708063170605
[19] Modan M, Halkin H, Almog S, 
Lusky A, Eshkol A, Shefi M, et al. 
Hyperinsulinemia. A link between 
hypertension obesity and glucose 
intolerance. The Journal of Clinical 
Investigation. 1985;75:809-817. DOI: 
10.1172/JCI111776
[20] Wirix AJ, Kaspers PJ, Nauta J, 
Chinapaw MJ, Kist-van Holthe JE.  
Pathophysiology of hypertension in 
obese children: A systematic review. 
Obesity Reviews. 2015;16:831-842. DOI: 
10.1111/obr.12305
[21] Hall JE, do Carmo JM, da Silva AA,  
Wang Z, Hall ME. Obesity-
induced hypertension: Interaction 
of neurohumoral and renal 
mechanisms. Circulation Research. 
2015;116:991-1006. DOI: 10.1161/
CIRCRESAHA.116.305697
[22] Kotsis V, Stabouli S, Papakatsika S,  
Rizos Z, Parati G. Mechanisms of 
obesity-induced hypertension. 
Hypertension Research. 2010;33: 
386-393. DOI: 10.1038/hr.2010.9
[23] Becton LJ, Shatat IF, Flynn JT.  
Hypertension and obesity: 
Epidemiology, mechanisms and clinical 
approach. Indian Journal of Pediatrics. 
2012;79:1056-1061. DOI: 10.1007/
s12098-012-0777-x
[24] Flynn J. The changing face of 
pediatric hypertension in the era of the 
childhood obesity epidemic. Pediatric 
Nephrology. 2013;28:1059-1066. DOI: 
10.1007/s00467-012-2344-0
[25] Grassi G, Seravalle G, Dell'Oro R, 
Turri C, Bolla GB, Mancia G. Adrenergic 
and reflex abnormalities in obesity-
related hypertension. Hypertension. 
2000;36:538-542
[26] Grassi G, Dell'Oro R, Facchini A,  
Quarti Trevano F, Bolla GB, 
Mancia G. Effect of central and 
peripheral body fat distribution on 
sympathetic and baroreflex function 
in obese normotensives. Journal of 
Hypertension. 2004;22:2363-2369
[27] Alvarez GE, Ballard TP, Beske SD,  
Davy KP. Subcutaneous obesity is 
not associated with sympathetic 
neural activation. American Journal 
of Physiology. Heart and Circulatory 
15
The “Weight” of Obesity on Arterial Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.87774
Physiology. 2004;287:H414-H418. DOI: 
10.1152/ajpheart.01046.2003
[28] Canoy D, Luben R, Welch A, 
Bingham S, Wareham N, Day N, et al. 
Fat distribution, body mass index and 
blood pressure in 22,090 men and 
women in the Norfolk cohort of the 
European Prospective Investigation into 
Cancer and Nutrition (EPIC-Norfolk) 
study. Journal of Hypertension. 
2004;22:2067-2074
[29] Hall JE, da Silva AA, do Carmo JM, 
Dubinion J, Hamza S, Munusamy S, 
et al. Obesity-induced hypertension: 
Role of sympathetic nervous system, 
leptin, and melanocortins. The 
Journal of Biological Chemistry. 
2010;285:17271-17276. DOI: 10.1074/jbc.
R110.113175
[30] Lohmeier TE, Iliescu R. The 
sympathetic nervous system in obesity 
hypertension. Current Hypertension 
Reports. 2013;15:409-416. DOI: 10.1007/
s11906-013-0356-1
[31] Aghamohammadzadeh R,  
Heagerty AM. Obesity-related 
hypertension: Epidemiology, 
pathophysiology, treatments, and 
the contribution of perivascular 
adipose tissue. Annals of Medicine. 
2012;44(Suppl 1):S74-S84. DOI: 
10.3109/07853890.2012.663928
[32] DeMarco VG, Aroor AR, 
Sowers JR. The pathophysiology of 
hypertension in patients with obesity. 
Nature Reviews. Endocrinology. 
2014;10:364-376. DOI: 10.1038/
nrendo.2014.44
[33] Rumantir MS, Vaz M, Jennings GL,  
Collier G, Kaye DM, Seals DR, et al. 
Neural mechanisms in human obesity-
related hypertension. Journal of 
Hypertension. 1999;17:1125-1133
[34] Kassab S, Kato T, Wilkins FC, 
Chen R, Hall JE, Granger JP. Renal 
denervation attenuates the sodium 
retention and hypertension associated 
with obesity. Hypertension. 
1995;25:893-897
[35] Lansberg L. Hypertension in 
the Twentieth Century: Concepts 
and Achievements: Handbook of 
Hypertension. Vol. 22. Amsterdam, 
Netherlands: Elsevier; 2004. pp. 245-261
[36] Hausberg M, Mark AL, Hoffman RP, 
Sinkey CA, Anderson EA. Dissociation 
of sympathoexcitatory and vasodilator 
actions of modestly elevated plasma 
insulin levels. Journal of Hypertension. 
1995;13:1015-1021
[37] Grassi G, Seravalle G, Colombo M, 
Bolla G, Cattaneo BM, Cavagnini F,  
et al. Body weight reduction, 
sympathetic nerve traffic, and 
arterial baroreflex in obese 
normotensive humans. Circulation. 
1998;97:2037-2042
[38] DeFronzo RA. Insulin and renal 
sodium handling: Clinical implications. 
International Journal of Obesity. 
1981;5(suppl 1):93-104
[39] Kennedy A, Gettys TW, Watson P,  
Wallace P, Ganaway E, Pan Q , et al. 
The metabolic significance of leptin 
in humans: Gender-based differences 
in relationship to adiposity, insulin 
sensitivity, and energy expenditure. The 
Journal of Clinical Endocrinology and 
Metabolism. 1997;82:1293-1300. DOI: 
10.1210/jcem.82.4.3859
[40] Tang-Christensen M, Havel PJ, 
Jacobs RR, Larsen PJ, Cameron JL.  
Central administration of leptin 
inhibits food intake and activates the 
sympathetic nervous system in rhesus 
macaques. The Journal of Clinical 
Endocrinology and Metabolism. 
1999;84:711-717. DOI: 10.1210/
jcem.84.2.5458
[41] Azar ST, Salti I, Zantout MS, 
Shahine CH, Zalloua PA. Higher serum 
leptin level in women than in men 
Crosstalk in Biological Processes
16
with type 1 diabetes. The American 
Journal of the Medical Sciences. 
2002;323:206-209
[42] Chrysant SG. Pathophysiology 
and treatment of obesity-related 
hypertension. Journal of Clinical 
Hypertension (Greenwich). 
2019;21(5):555-559. DOI: 10.1111/
jch.13518
[43] Shek EW, Brands MW, Hall JE.  
Chronic leptin infusion increases 
arterial pressure. Hypertension. 
1998;31:409-414
[44] Dunbar JC, Hu Y, Lu H.  
Intracerebroventricular leptin increases 
lumbar and renal sympathetic nerve 
activity and blood pressure in normal 
rats. Diabetes. 1997;46:2040-2043
[45] Landsberg L. Diet, obesity and 
hypertension: An hypothesis involving 
insulin, the sympathetic nervous 
system, and adaptive thermogenesis. 
The Quarterly Journal of Medicine. 
1986;61:1081-1090
[46] Bentley-Lewis R, Adler GK, 
Perlstein T, Seely EW, Hopkins PN, 
Williams GH, et al. Body mass index 
predicts aldosterone production in 
normotensive adults on a high-salt diet. 
The Journal of Clinical Endocrinology 
and Metabolism. 2007;92:4472-4475. 
DOI: 10.1210/jc.2007-1088
[47] Goodfriend TL, Kelley DE,  
Goodpaster BH, Winters SJ. Visceral 
obesity and insulin resistance are associated 
with plasma aldosterone levels in women. 
Obesity Research. 1999;7:355-362
[48] Nagase M, Yoshida S, Shibata S, 
Nagase T, Gotoda T, Ando K, et al. 
Enhanced aldosterone signaling 
in the early nephropathy of rats 
with metabolic syndrome: Possible 
contribution of fat-derived factors. 
Journal of the American Society of 
Nephrology. 2006;17:3438-3446.  
DOI: 10.1681/ASN.2006080944
[49] Jeon JH, Kim KY, Kim JH, Baek A,  
Cho H, Lee YH, et al. A novel adipokine 
CTRP1 stimulates aldosterone 
production. The FASEB Journal. 
2008;22:1502-1511. DOI: 10.1096/
fj.07-9412com
[50] Kawarazaki W, Fujita T. The role 
of aldosterone in obesity-related 
hypertension. American Journal of 
Hypertension. 2016;29:415-423. DOI: 
10.1093/ajh/hpw003
[51] Engeli S, Sharma AM. The renin-
angiotensin system and natriuretic 
peptides in obesity-associated 
hypertension. Journal of Molecular 
Medicine (Berlin, Germany). 
2001;79:21-29
[52] Marcus Y, Shefer G, Stern N.  
Adipose tissue renin-angiotensin-
aldosterone system (RAAS) and 
progression of insulin resistance. 
Molecular and Cellular Endocrinology. 
2013;378:1-14. DOI: 10.1016/j.
mce.2012.06.021
[53] Cassis LA, Police SB, Yiannikouris F, 
 Thatcher SE. Local adipose tissue 
renin-angiotensin system. Current 
Hypertension Reports. 2008;10:93-98
[54] Yasue S, Masuzaki H, Okada S, 
Ishii T, Kozuka C, Tanaka T, et al. 
Adipose tissue-specific regulation of 
angiotensinogen in obese humans and 
mice: Impact of nutritional status and 
adipocyte hypertrophy. American 
Journal of Hypertension. 2010;23: 
425-431. DOI: 10.1038/ajh.2009.263
[55] Yiannikouris F, Gupte M,  
Putnam K, Thatcher S, Charnigo R,  
Rateri DL, et al. Adipocyte deficiency 
of angiotensinogen prevents 
obesity-induced hypertension 
in male mice. Hypertension. 
2012;60:1524-1530. DOI: 10.1161/
HYPERTENSIONAHA.112.192690
[56] Karlsson C, Lindell K,  
Ottosson M, Sjostrom L, Carlsson B,  
17
The “Weight” of Obesity on Arterial Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.87774
Carlsson LM. Human adipose tissue 
expresses angiotensinogen and 
enzymes required for its conversion to 
angiotensin II. The Journal of Clinical 
Endocrinology and Metabolism. 
1998;83:3925-3929. DOI: 10.1210/
jcem.83.11.5276
[57] Seravalle G, Colombo M, Perego P, 
Giardini V, Volpe M, Dell'Oro R, et al. 
Long-term sympathoinhibitory effects 
of surgically induced weight loss in 
severe obese patients. Hypertension. 
2014;64:431-437. DOI: 10.1161/
HYPERTENSIONAHA.113.02988
[58] Tuck ML, Sowers J, Dornfeld L, 
Kledzik G, Maxwell M. The effect of 
weight reduction on blood pressure, 
plasma renin activity, and plasma 
aldosterone levels in obese patients. 
The New England Journal of Medicine. 
1981;304:930-933. DOI: 10.1056/
NEJM198104163041602
[59] Rocchini AP, Katch VL, Grekin R,  
Moorehead C, Anderson J. Role 
for aldosterone in blood pressure 
regulation of obese adolescents. The 
American Journal of Cardiology. 
1986;57:613-618
[60] Engeli S, Bohnke J, Gorzelniak K,  
Janke J, Schling P, Bader M, et al. 
Weight loss and the renin-angiotensin-
aldosterone system. Hypertension. 
2005;45:356-362. DOI: 10.1161/01.
HYP.0000154361.47683.d3
[61] Ruano M, Silvestre V, Castro R, 
Garcia-Lescun MC, Rodriguez A,  
Marco A, et al. Morbid obesity, 
hypertensive disease and the renin-
angiotensin-aldosterone axis. Obesity 
Surgery. 2005;15:670-676. DOI: 
10.1381/0960892053923734
[62] Goodfriend TL, Ball DL, Egan BM, 
Campbell WB, Nithipatikom K.  
Epoxy-keto derivative of linoleic acid 
stimulates aldosterone secretion. 
Hypertension. 2004;43:358-363. DOI: 
10.1161/01.HYP.0000113294.06704.64
[63] Naguib MT. Kidney disease in the 
obese patient. Southern Medical Journal. 
2014;107:481-485. DOI: 10.14423/
SMJ.0000000000000141
[64] Hall JE, Brands MW, Dixon WN,  
Smith MJ Jr. Obesity-induced 
hypertension. Renal function and 
systemic hemodynamics. Hypertension. 
1993;22:292-299
[65] Tchernof A, Despres JP.  
Pathophysiology of human visceral 
obesity: An update. Physiological 
Reviews. 2013;93:359-404. DOI: 
10.1152/physrev.00033.2011
[66] Carroll JF, Huang M, Hester RL, 
Cockrell K, Mizelle HL. Hemodynamic 
alterations in hypertensive obese 
rabbits. Hypertension. 1995;26:465-470
[67] Hall ME, do Carmo JM, da Silva AA, 
Juncos LA, Wang Z, Hall JE. Obesity, 
hypertension, and chronic kidney 
disease. International Journal of 
Nephrology and Renovascular Disease. 
2014;7:75-88. DOI: 10.2147/IJNRD.
S39739
[68] Ahmed SB, Fisher ND, Stevanovic R, 
Hollenberg NK. Body mass index and 
angiotensin-dependent control of the 
renal circulation in healthy humans. 
Hypertension. 2005;46:1316-1320. DOI: 
10.1161/01.HYP.0000190819.07663.da
[69] Frigolet ME, Torres N, Tovar AR.  
The renin-angiotensin system in adipose 
tissue and its metabolic consequences 
during obesity. The Journal of Nutritional 
Biochemistry. 2013;24:2003-2015. DOI: 
10.1016/j.jnutbio.2013.07.002
[70] Sun K, Tordjman J, Clement K, 
Scherer PE. Fibrosis and adipose 
tissue dysfunction. Cell Metabolism. 
2013;18:470-477. DOI: 10.1016/j.
cmet.2013.06.016
[71] Guzik TJ, Skiba DS, Touyz RM, 
Harrison DG. The role of infiltrating 
immune cells in dysfunctional adipose 
Crosstalk in Biological Processes
18
tissue. Cardiovascular Research. 
2017;113:1009-1023. DOI: 10.1093/cvr/
cvx108
[72] Ronti T, Lupattelli G, Mannarino E.  
he endocrine function of adipose 
tissue: An update. Clinical 
Endocrinology. 2006;64:355-365. DOI: 
10.1111/j.1365-2265.2006.02474.x
[73] Mikolajczyk TP, Nosalski R, 
Szczepaniak P, Budzyn K, Osmenda G,  
Skiba D, et al. Role of chemokine 
RANTES in the regulation of perivascular 
inflammation, T-cell accumulation, and 
vascular dysfunction in hypertension. 
The FASEB Journal. 2016;30:1987-1999. 
DOI: 10.1096/fj.201500088R
[74] Marvar PJ, Thabet SR, Guzik TJ, 
Lob HE, McCann LA, Weyand C, et al. 
Central and peripheral mechanisms of 
T-lymphocyte activation and vascular 
inflammation produced by angiotensin 
II-induced hypertension. Circulation 
Research. 2010;107:263-270. DOI: 
10.1161/CIRCRESAHA.110.217299
[75] Wilk G, Osmenda G, Matusik P, 
Nowakowski D, Jasiewicz-Honkisz B,  
Ignacak A, et al. Endothelial function 
assessment in atherosclerosis: 
Comparison of brachial artery 
flowmediated vasodilation and 
peripheral arterial tonometry. Polskie 
Archiwum Medycyny Wewnętrznej. 
2013;123:443-452
[76] Guzik TJ, Hoch NE, Brown KA, 
McCann LA, Rahman A, Dikalov S, 
et al. Role of the T cell in the genesis of 
angiotensin II induced hypertension 
and vascular dysfunction. The 
Journal of Experimental Medicine. 
2007;204:2449-2460. DOI: 10.1084/
jem.20070657
[77] Nosalski R, McGinnigle E, 
Siedlinski M, Guzik TJ. Novel 
immune mechanisms in hypertension 
and cardiovascular risk. Current 
Cardiovascular Risk Reports. 2017;11:12. 
DOI: 10.1007/s12170-017-0537-6
[78] Guzik TJ, Olszanecki R, Sadowski J,  
Kapelak B, Rudzinski P, Jopek A, 
et al. Superoxide dismutase activity 
and expression in human venous and 
arterial bypass graft vessels. Journal 
of Physiology and Pharmacology. 
2005;56:313-323
[79] Coccagna G, Mantovani M, Brignani 
F, Parchi C, Lugaresi E. Continuous 
recording of the pulmonary and 
systemic arterial pressure during sleep in 
syndromes of hypersomnia with periodic 
breathing. Bulletin de Physio-Pathologie 
Respiratoire. 1972;8:1159-1172
[80] Marcus JA, Pothineni A,  
Marcus CZ, Bisognano JD. The role of 
obesity and obstructive sleep apnea 
in the pathogenesis and treatment 
of resistant hypertension. Current 
Hypertension Reports. 2014;16:411. 
DOI: 10.1007/s11906-013-0411-y
[81] Flegal KM, Carroll MD, Ogden CL, 
Curtin LR. Prevalence and trends in 
obesity among US adults, 1999-2008. 
JAMA. 2010;303:235-241. DOI: 10.1001/
jama.2009.2014
[82] Parati G, Pengo MF, Lombardi C.  
Obstructive sleep apnea and 
hypertension: Why treatment does 
not consistently improve blood 
pressure. Current Hypertension 
Reports. 2019;21:30. DOI: 10.1007/
s11906-019-0935-x
[83] Iturriaga R, Oyarce MP, Dias ACR.  
Role of carotid body in intermittent 
hypoxia-related hypertension. Current 
Hypertension Reports. 2017;19:38. DOI: 
10.1007/s11906-017-0735-0
[84] Khan A, Patel NK, O'Hearn 
DJ, Khan S. Resistant hypertension 
and obstructive sleep apnea. 
International Journal of Hypertension. 
2013;2013:193010. DOI: 
10.1155/2013/193010
[85] Phillips BG, Narkiewicz K, Pesek CA, 
Haynes WG, Dyken ME, Somers VK.  
19
The “Weight” of Obesity on Arterial Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.87774
Effects of obstructive sleep apnea 
on endothelin-1 and blood pressure. 
Journal of Hypertension. 1999;17:61-66
[86] Belaidi E, Joyeux-Faure M, Ribuot C, 
Launois SH, Levy P, Godin-Ribuot D.  
Major role for hypoxia inducible factor-1 
and the endothelin system in promoting 
myocardial infarction and hypertension 
in an animal model of obstructive sleep 
apnea. Journal of the American College 
of Cardiology. 2009;53:1309-1317. DOI: 
10.1016/j.jacc.2008.12.050
[87] Hla KM, Young T, Finn L, Peppard 
PE, Szklo-Coxe M, Stubbs M.  
Longitudinal association of sleep-
disordered breathing and nondipping 
of nocturnal blood pressure in the 
Wisconsin Sleep Cohort Study. 
Sleep. 2008;31:795-800
[88] James PA, Oparil S, Carter BL, 
Cushman WC, Dennison-Himmelfarb 
C, Handler J, et al. 2014 evidence-based 
guideline for the management of high 
blood pressure in adults: Report from 
the panel members appointed to the 
Eighth Joint National Committee  
(JNC 8). JAMA. 2014;311:507-520. DOI: 
10.1001/jama.2013.284427
[89] Williams B, Mancia G, Spiering W, 
Agabiti Rosei E, Azizi M, Burnier M, 
et al. 2018 ESC/ESH guidelines for the 
management of arterial hypertension. 
European Heart Journal. 2018;39: 
3021-3104. DOI: 10.1093/eurheartj/
ehy339
[90] Iqbal AM, Jamal SF. Essential 
Hypertension. Treasure Island (FL): 
StatPearls; 2019
[91] Jandeleit-Dahm KA, Tikellis C,  
Reid CM, Johnston CI, Cooper ME. Why 
blockade of the renin-angiotensin 
system reduces the incidence of new-
onset diabetes. Journal of Hypertension. 
2005;23:463-473
[92] Sharma AM, Engeli S. The 
role of renin-angiotensin system 
blockade in the management of 
hypertension associated with the 
cardiometabolic syndrome. Journal 
of the Cardiometabolic Syndrome. 
2006;1:29-35
[93] Gupta AK, Dahlof B, Dobson J, 
Sever PS, Wedel H, Poulter NR. Anglo-
Scandinavian Cardiac Outcomes Trial, I.  
Determinants of new-onset diabetes 
among 19,257 hypertensive patients 
randomized in the Anglo-Scandinavian 
Cardiac Outcomes Trial--Blood Pressure 
Lowering rm and the relative influence 
of antihypertensive medication. 
Diabetes Care. 2008;31:982-988. DOI: 
10.2337/dc07-1768
[94] Lardizabal JA, Deedwania PC. The 
role of renin-angiotensin agents in 
altering the natural history of type 2 
diabetes mellitus. Current Cardiology 
Reports. 2010;12:464-471. DOI: 10.1007/
s11886-010-0138-1
[95] Lavie CJ, Patel DA, Milani 
RV, Ventura HO, Shah S, Gilliland 
Y. Impact of echocardiographic left 
ventricular geometry on clinical 
prognosis. Progress in Cardiovascular 
Diseases. 2014;57:3-9. DOI: 10.1016/j.
pcad.2014.05.003
[96] Artham SM, Lavie CJ, Milani RV, 
Patel DA, Verma A, Ventura HO.  
Clinical impact of left ventricular 
hypertrophy and implications for 
regression. Progress in Cardiovascular 
Diseases. 2009;52:153-167. DOI: 
10.1016/j.pcad.2009.05.002
[97] Wing LM, Reid CM, Ryan P, 
Beilin LJ, Brown MA, Jennings GL, 
et al. A comparison of outcomes with 
angiotensin-converting--enzyme 
inhibitors and diuretics for hypertension 
in the elderly. The New England Journal 
of Medicine. 2003;348:583-592. DOI: 
10.1056/NEJMoa021716
[98] The Seventh Report of the Joint 
National Committee on Prevention, 
Detection, Evaluation, and Treatment 
Crosstalk in Biological Processes
20
of High Blood Pressure. USA: Bethesda 
(MD); 2004
[99] Cooper-DeHoff RM, Wen S, 
Beitelshees AL, Zineh I, Gums JG,  
Turner ST, et al. Impact of 
abdominal obesity on incidence 
of adverse metabolic effects 
associated with antihypertensive 
medications. Hypertension. 
2010;55:61-68. DOI: 10.1161/
HYPERTENSIONAHA.109.139592
[100] Torre JJ, Bloomgarden ZT,  
Dickey RA, Hogan MJ, Janick JJ, 
Jyothinagaram SG, et al. American 
Association of Clinical Endocrinologists 
Medical Guidelines for Clinical Practice 
for the diagnosis and treatment of 
hypertension. Endocrine Practice. 
2006;12:193-222
[101] Habibi J, Whaley-Connell A, 
Hayden MR, DeMarco VG, Schneider R,  
Sowers SD, et al. Renin inhibition 
attenuates insulin resistance, oxidative 
stress, and pancreatic remodeling in 
the transgenic Ren2 rat. Endocrinology. 
2008;149:5643-5653. DOI: 10.1210/
en.2008-0070
[102] Lee P, Kengne AP, Greenfield JR, 
Day RO, Chalmers J, Ho KK. Metabolic 
sequelae of beta-blocker therapy: 
Weighing in on the obesity epidemic? 
International Journal of Obesity. 
2011;35:1395-1403. DOI: 10.1038/
ijo.2010.284
[103] Messerli FH, Bell DS, Fonseca V, 
Katholi RE, McGill JB, Phillips RA, 
et al. Body weight changes with beta-
blocker use: Results from GEMINI. The 
American Journal of Medicine. 
2007;120:610-615. DOI: 10.1016/j.
amjmed.2006.10.017
[104] Kidambi S, Kotchen TA. Treatment 
of hypertension in obese patients. 
American Journal of Cardiovascular 
Drugs. 2013;13:163-175. DOI: 10.1007/
s40256-013-0008-5
[105] Schmieder RE, Gatzka C, 
Schachinger H, Schobel H, Ruddel H.  
Obesity as a determinant for response 
to antihypertensive treatment. BMJ. 
1993;307:537-540. DOI: 10.1136/
bmj.307.6903.537
[106] Stoa-Birketvedt G, Thom E, 
Aarbakke J, Florholmen J. Body fat as 
a predictor of the antihypertensive 
effect of nifedipine. Journal of Internal 
Medicine. 1995;237:169-173
[107] Zhang R, Thakur V, 
Morse S, Reisin E. Renal and 
cardiovascular considerations 
for the nonpharmacological and 
pharmacological therapies of obesity-
hypertension. Journal of Human 
Hypertension. 2002;16:819-827. DOI: 
10.1038/sj.jhh.1001496
[108] Bakris GL, Copley JB, Vicknair N, 
Sadler R, Leurgans S. Calcium channel 
blockers versus other antihypertensive 
therapies on progression of NIDDM 
associated nephropathy. Kidney 
International. 1996;50:1641-1650
[109] Hummel D, Raff U, Schwarz TK,  
Schneider MP, Schmieder RE,  
Schmidt BM. Dihydropyridine calcium 
antagonists are associated with 
increased albuminuria in treatment-
resistant hypertensives. Journal of 
Nephrology. 2010;23:563-568
[110] Gress TW, Nieto FJ, Shahar E, 
Wofford MR, Brancati FL. Hypertension 
and antihypertensive therapy as risk 
factors for type 2 diabetes mellitus. 
Atherosclerosis Risk in Communities 
Study. The New England Journal of 
Medicine. 2000;342:905-912. DOI: 
10.1056/NEJM200003303421301
[111] Weber MA, Jamerson K, Bakris 
GL, Weir MR, Zappe D, Zhang Y, et al. 
Effects of body size and hypertension 
treatments on cardiovascular event 
rates: Subanalysis of the ACCOMPLISH 
randomised controlled trial. Lancet. 
21
The “Weight” of Obesity on Arterial Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.87774
2013;381:537-545. DOI: 10.1016/
S0140-6736(12)61343-9
[112] Dahlof B, Sever PS, Poulter NR, 
Wedel H, Beevers DG, Caulfield M, 
et al. Prevention of cardiovascular 
events with an antihypertensive regimen 
of amlodipine adding perindopril 
as required versus atenolol adding 
bendroflumethiazide as required, in the 
Anglo-Scandinavian Cardiac Outcomes 
Trial-Blood Pressure Lowering Arm 
(ASCOT-BPLA): A multicentre 
randomised controlled trial. Lancet. 
2005;366:895-906. DOI: 10.1016/
S0140-6736(05)67185-1
[113] Wofford MR, Smith G, Minor DS.  
The treatment of hypertension in obese 
patients. Current Hypertension Reports. 
2008;10:143-150
[114] Noce A, Marrone G, Rovella V, 
Busca A, Gola C, Ferrannini M, et al. 
Fenoldopam mesylate: A narrative 
review of its use in acute kidney injury. 
Current Pharmaceutical Biotechnology. 
2019;20(5). DOI: 10.2174/1389201020666
190417124711
[115] Rovella V, Ferrannini M,  
Tesauro M, Marrone G, Busca A,  
Sorge R, et al. Effects of fenoldopam on 
renal blood flow in hypertensive chronic 
kidney disease. Journal of Nephrology. 
2019;32:75-81. DOI: 10.1007/
s40620-018-0496-0
[116] Cataldi M, di Geronimo O,  
Trio R, Scotti A, Memoli A, Capone D, 
et al. Utilization of antihypertensive 
drugs in obesity-related hypertension: 
A retrospective observational study 
in a cohort of patients from Southern 
Italy. BMC Pharmacology and 
Toxicology. 2016;17:9. DOI: 10.1186/
s40360-016-0055-z
[117] NHLBI Obesity Education 
Initiative Expert Panel on the 
Identification E, Treatment of Obesity 
in Adults (US). Clinical Guidelines 
on the Identification, Evaluation, and 
Treatment of Overweight and Obesity 
in Adults. USA: National Heart, Lung, 
and Blood Institute; 1998
[118] Snow V, Barry P, Fitterman N, 
Qaseem A, Weiss K. Clinical Efficacy 
Assessment Subcommittee of the 
American College of, P. Pharmacologic 
and surgical management of obesity 
in primary care: A clinical practice 
guideline from the American College of 
Physicians. Annals of Internal Medicine. 
2005;142:525-531
[119] Scheen AJ. Sibutramine on 
cardiovascular outcome. Diabetes Care. 
2011;34(Suppl 2):S114-S119. DOI: 
10.2337/dc11-s205
[120] Derosa G, Cicero AF, Murdolo G,  
Piccinni MN, Fogari E, Bertone G, 
et al. Efficacy and safety comparative 
evaluation of orlistat and sibutramine 
treatment in hypertensive obese 
patients. Diabetes, Obesity & 
Metabolism. 2005;7:47-55. DOI: 
10.1111/j.1463-1326.2004.00372.x
[121] Over-the-counter weight loss 
with orlistat? Evidence-Based Nursing. 
2010;13:98-100. DOI: 10.1136/
dtb.2009.10.0046
[122] Guerciolini R. Mode of action of 
orlistat. International Journal of Obesity 
and Related Metabolic Disorders. 
1997;21(Suppl 3):S12-S23
[123] Rossner S, Sjostrom L, Noack R, 
Meinders AE, Noseda G. Weight loss, 
weight maintenance, and improved 
cardiovascular risk factors after 2 years 
treatment with orlistat for obesity. 
European Orlistat Obesity Study Group. 
Obesity Research. 2000;8:49-61. DOI: 
10.1038/oby.2000.8
[124] Brown SA, Upchurch S, Anding R,  
Winter M, Ramirez G. Promoting 
weight loss in type II diabetes. Diabetes 
Care. 1996;19:613-624
Crosstalk in Biological Processes
22
[125] Hauner H, Petzinna D, 
Sommerauer B, Toplak H. Effect of 
acarbose on weight maintenance after 
dietary weight loss in obese subjects. 
Diabetes, Obesity & Metabolism. 
2001;3:423-427
[126] Lawrence CB, Turnbull AV, 
Rothwell NJ. Hypothalamic control 
of feeding. Current Opinion in 
Neurobiology. 1999;9:778-783
[127] Garfield AS, Lam DD, Marston OJ, 
Przydzial MJ, Heisler LK. Role of central 
melanocortin pathways in energy 
homeostasis. Trends in Endocrinology 
and Metabolism. 2009;20:203-215. DOI: 
10.1016/j.tem.2009.02.002
[128] Smitka K, Papezova H, Vondra K, 
Hill M, Hainer V, Nedvidkova J. The role 
of "mixed" orexigenic and anorexigenic 
signals and autoantibodies reacting 
with appetite-regulating neuropeptides 
and peptides of the adipose tissue-gut-
brain axis: Relevance to food intake 
and nutritional status in patients 
with anorexia nervosa and bulimia 
nervosa. International Journal of 
Endocrinology. 2013;2013:483145. DOI: 
10.1155/2013/483145
[129] Jollis JG, Landolfo CK, Kisslo J, 
Constantine GD, Davis KD, Ryan T. 
Fenfluramine and phentermine and 
cardiovascular findings: Effect of 
treatment duration on prevalence 
of valve abnormalities. Circulation. 
2000;101:2071-2077
[130] Gustafson A, King C, Rey JA. 
Lorcaserin (Belviq): A selective 
serotonin 5-HT2C agonist In 
the treatment of obesity. PT. 
2013;38:525-534
[131] Smith SR, Weissman NJ, 
Anderson CM, Sanchez M, Chuang E, 
Stubbe S, et al. Multicenter, placebo-
controlled trial of lorcaserin for weight 
management. The New England Journal 
of Medicine. 2010;363:245-256. DOI: 
10.1056/NEJMoa0909809
[132] Ioannides-Demos LL, Piccenna L,  
McNeil JJ. Pharmacotherapies 
for obesity: Past, current, and 
future therapies. Journal of 
Obesity. 2011;2011:179674. DOI: 
10.1155/2011/179674
[133] Kaplan LM. Pharmacological 
therapies for obesity. Gastroenterology 
Clinics of North America. 2005;34: 
91-104. DOI: 10.1016/j.gtc.2004.12.002
[134] Patel DK, Stanford FC. Safety 
and tolerability of new-generation 
anti-obesity medications: A 
narrative review. Postgraduate 
Medicine. 2018;130:173-182. DOI: 
10.1080/00325481.2018.1435129
[135] Levri KM, Slaymaker E, Last A,  
Yeh J, Ference J, D'Amico F, et al. 
Metformin as treatment for overweight 
and obese adults: A systematic review. 
Annals of Family Medicine. 2005;3: 
457-461. DOI: 10.1370/afm.343
[136] Diabetes Prevention Program 
Research, G. The diabetes prevention 
program (DPP): Description of 
lifestyle intervention. Diabetes Care. 
2002;25:2165-2171
[137] Robinson AC, Burke J, Robinson S, 
Johnston DG, Elkeles RS. The effects 
of metformin on glycemic control 
and serum lipids in insulin-treated 
NIDDM patients with suboptimal 
metabolic control. Diabetes Care. 
1998;21:701-705
[138] Kim W, Egan JM. The role of 
incretins in glucose homeostasis and 
diabetes treatment. Pharmacological 
Reviews. 2008;60:470-512. DOI: 
10.1124/pr.108.000604
[139] Brown NJ. Cardiovascular effects 
of antidiabetic agents: Focus on blood 
pressure effects of incretin-based 
therapies. Journal of the American 
Society of Hypertension. 2012;6: 
163-168. DOI: 10.1016/j.
jash.2012.02.003
23
The “Weight” of Obesity on Arterial Hypertension
DOI: http://dx.doi.org/10.5772/intechopen.87774
[140] Horton ES, Silberman C, Davis KL, 
Berria R. Weight loss, glycemic 
control, and changes in cardiovascular 
biomarkers in patients with type 2 
diabetes receiving incretin therapies 
or insulin in a large cohort database. 
Diabetes Care. 2010;33:1759-1765. DOI: 
10.2337/dc09-2062
[141] Jiang SZ, Lu W, Zong XF, Ruan HY,  
Liu Y. Obesity and hypertension. 
Experimental and Therapeutic 
Medicine. 2016;12:2395-2399. DOI: 
10.3892/etm.2016.3667
[142] Collaboration, 
N.C.D.R.F. Worldwide trends in body-
mass index, underweight, overweight, 
and obesity from 1975 to 2016: A pooled 
analysis of 2416 population-based 
measurement studies in 128.9 million 
children, adolescents, and adults. 
Lancet. 2017;390(17):2627, 32129-2642, 
32123. DOI: 10.1016/S0140-6736
[143] Kotchen TA. Obesity-related 
hypertension: Epidemiology, 
pathophysiology, and clinical 
management. American Journal of 
Hypertension. 2010;23:1170-1178. DOI: 
10.1038/ajh.2010.172
[144] Racette SB, Deusinger SS,  
Strube MJ, Highstein GR, Deusinger RH.  
Weight changes, exercise, and dietary 
patterns during freshman and sophomore 
years of college. Journal of American 
College Health. 2005;53:245-251. DOI: 
10.3200/JACH.53.6.245-251
[145]  Mirowsky J, Ross CE. Social Causes 
of Psychological Distress. 2nd edition. 
New York, USA: Aldine Transaction; 2003
[146] Bray GA. Lifestyle and 
pharmacological approaches to weight 
loss: Efficacy and safety. The Journal of 
Clinical Endocrinology and Metabolism. 
2008;93:S81-S88. DOI: 10.1210/
jc.2008-1294
[147] Your Guide to Lowering Your Blood 
Pressure with DASH. U.S. Department 
of Health and Human Services National 
Institutes of Health National Heart, 
Lung, and Blood Institute. Bethesda, 
MD, USA: NHLBI Publications and 
Resources; 2006
[148] Ding D, Lawson KD, Kolbe-
Alexander TL, Finkelstein EA, 
Katzmarzyk PT, van Mechelen W, 
et al. The economic burden of physical 
inactivity: A global analysis of major 
non-communicable diseases. Lancet. 
2016;388:1311-1324. DOI: 10.1016/
S0140-6736(16)30383-X
[149] Cornelissen VA, Smart NA. 
Exercise training for blood pressure: A 
systematic review and meta-analysis. 
Journal of the American Heart 
Association. 2013;2:e004473. DOI: 
10.1161/JAHA.112.004473
[150] Naci H, Ioannidis JP. Comparative 
effectiveness of exercise and drug 
interventions on mortality outcomes: 
Metaepidemiological study. 
British Journal of Sports Medicine. 
2015;49:1414-1422. DOI: 10.1136/
bjsports-2015-f5577rep
[151] Dempsey PC, Sacre JW, Larsen RN, 
Straznicky NE, Sethi P, Cohen ND, 
et al. Interrupting prolonged sitting 
with brief bouts of light walking 
or simple resistance activities 
reduces resting blood pressure and 
plasma noradrenaline in type 2 
diabetes. Journal of Hypertension. 
2016;34:2376-2382. DOI: 10.1097/
HJH.0000000000001101
[152] The Health Benefits of Smoking 
Cessation: A Report of the Surgeon 
General. United States: Public Health 
Service. Rockvllle, Maryland USA: 
Office of the Surgeon General; 1990
[153] Bush T, Lovejoy JC, Deprey M, 
Carpenter KM. The effect of tobacco 
cessation on weight gain, obesity, and 
diabetes risk. Obesity (Silver Spring). 
2016;24:1834-1841. DOI: 10.1002/
oby.21582
Crosstalk in Biological Processes
24
[154] Gruber J, Frakes M. Does falling 
smoking lead to rising obesity? Journal 
of Health Economics. 2006;25:183-197; 
discussion 389-193. DOI: 10.1016/j.
jhealeco.2005.07.005
[155] Traversy G, Chaput JP. Alcohol 
consumption and obesity: An update. 
Current Obesity Reports. 2015;4:122-130. 
DOI: 10.1007/s13679-014-0129-4
[156] Bendsen NT, Christensen R,  
Bartels EM, Kok FJ, Sierksma A, Raben 
A, et al. Is beer consumption related 
to measures of abdominal and general 
obesity? A systematic review and meta-
analysis. Nutrition Reviews. 2013;71:67-87. 
DOI: 10.1111/j.1753-4887.2012.00548.x
